Compare · MDLN vs PRCT
MDLN vs PRCT
Side-by-side comparison of Medline Inc. (MDLN) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 46.3x PRCT ($1.04B).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 6 for PRCT).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- PROCEPT BioRobotics Corporation
- Price
- -
- -
- Market cap
- $48.08B
- $1.04B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 25
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest PRCT
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
- Barclays initiated coverage on PROCEPT BioRobotics with a new price target
- SEC Form 4 filed by PROCEPT BioRobotics Corporation
- SEC Form 3 filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- EVP, CLO, CORP. SEC. Nouri Alaleh sold $6,223 worth of shares (297 units at $20.95), decreasing direct ownership by 0.23% to 127,737 units (SEC Form 4) to cover withholding tax
- EVP, Chief Technology Officer Templin Barry L sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.39% to 94,826 units (SEC Form 4) to cover withholding tax
- EVP, CFO Waters Kevin sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.21% to 180,355 units (SEC Form 4) to satisfy withholding tax
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026